• Apr 9, 2024 from 1:00 to 2:00
  • Location: Online Event
  • Latest Activity: Apr 5

OVERVIEW

AI/ ML will revolutionize medicine by making diagnosis and treatment more accessible and more effective.
FDA has regulated medical software using regulations and guidance for years, however, AI/ML programs fall outside the scope of these regulations and guidances.

This happens because the FDA approves the final, validated version of the software. The point of AI/ML is to learn and update following deployment to improve performance. Thus the field version of the software is no longer the validated approved version.

We will discuss the current regulatory requirements, how they don’t control AI/ML adequately, and approaches the FDA is considering for regulation shortly. Your development program should conform to these concepts now because, with some modifications, they will probably become regulations.

Following a discussion of possible future regulations, we will discuss, based on recently approved De Novo applications, how to get your AI/ML program approved now. Necessary submission documentation will be explained.

This webinar is not a programming course but will explain the present and future regulatory requirements for AI/ML.

AREA COVERED

  • Total product life cycle approach to AI/ ML design
  • Application of FDA software Pre Cert program to AI/ ML
  • FDA discussion paper on AI/ML
  • Database management
  • QC of datasets
  • Algorithm updating
  • Reference standard development
  • Standalone performance testing
  • Clinical performance testing
  • Data Enrichment
  • Emphasis on "explainability"
  • Additional labeling requirements
  • Cybersecurity

WHY SHOULD YOU ATTEND

  • It is not clear how to get AI/ML programs approved. The current regulatory requirements don’t control AI/ML adequately.
  • We will discuss the approaches FDA is considering for regulation shortly and how to get your AI/ML program approved by FDA now.
  • Necessary submission documentation will be explained Attendees will receive a multipage outline and checklist.

WHO WILL BENEFIT?

Managers, Supervisors, Directors, and Vice-Presidents in the areas of:

  • Software Engineers
  • Engineers
  • Regulatory Personnel
  • Quality Assurance Personnel
  • Marketing
  • Management

 

https://247compliance.us/fda-regulation-of-artificial-intelligence-machine-learning/1752?through=RuthMartine_5thApr_IN&sm_grc

E-mail me when people leave their comments –

You need to be a member of Global Risk Community to add comments!

Join Global Risk Community

Upcoming Featured events

 

    About Us

    The GlobalRisk Community is a thriving community of risk managers and associated service providers. Our purpose is to foster business, networking and educational explorations among members. Our goal is to be the worlds premier Risk forum and contribute to better understanding of the complex world of risk.

    Business Partners

    For companies wanting to create a greater visibility for their products and services among their prospects in the Risk market: Send your business partnership request by filling in the form here!

lead